Swiss National Bank grew its holdings in Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) by 2.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 91,900 shares of the company’s stock after buying an additional 2,100 shares during the quarter. Swiss National Bank owned 0.23% of Cassava Sciences worth $2,715,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in SAVA. Marshall Wace LLP acquired a new position in shares of Cassava Sciences in the 3rd quarter valued at $6,579,000. State Street Corp increased its position in shares of Cassava Sciences by 8.0% during the 1st quarter. State Street Corp now owns 1,053,956 shares of the company’s stock worth $39,144,000 after purchasing an additional 77,830 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cassava Sciences by 3.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,109,863 shares of the company’s stock worth $88,235,000 after purchasing an additional 62,151 shares in the last quarter. Clear Creek Financial Management LLC increased its position in shares of Cassava Sciences by 323.6% during the 4th quarter. Clear Creek Financial Management LLC now owns 67,270 shares of the company’s stock worth $1,987,000 after purchasing an additional 51,390 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Cassava Sciences by 589.4% during the 4th quarter. SG Americas Securities LLC now owns 35,437 shares of the company’s stock worth $1,047,000 after purchasing an additional 30,297 shares in the last quarter. Institutional investors and hedge funds own 25.51% of the company’s stock.
Insider Buying and Selling at Cassava Sciences
In other Cassava Sciences news, Director Richard Barry bought 11,565 shares of Cassava Sciences stock in a transaction dated Monday, March 6th. The shares were bought at an average price of $26.13 per share, with a total value of $302,193.45. Following the purchase, the director now owns 197,724 shares of the company’s stock, valued at $5,166,528.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 10.10% of the company’s stock.
Cassava Sciences Trading Up 0.4 %
Cassava Sciences (NASDAQ:SAVA – Get Rating) last posted its quarterly earnings data on Monday, May 1st. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.02). On average, research analysts predict that Cassava Sciences, Inc. will post 0.84 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on SAVA. HC Wainwright reiterated a “buy” rating and set a $124.00 target price on shares of Cassava Sciences in a research report on Monday, March 6th. B. Riley dropped their target price on shares of Cassava Sciences from $44.00 to $28.00 in a research report on Wednesday, January 25th.
Cassava Sciences Profile
Cassava Sciences, Inc engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
- Get a free copy of the StockNews.com research report on Cassava Sciences (SAVA)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.